文献速递银屑病与炎症性皮肤病

托法替布治疗中重度银屑病患者对肺炎球菌结合疫苗和破伤风类毒素疫苗的T细胞介导免疫应答

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
PubMed 文献 · J Am Acad Dermatol · 2018-03-02

研究评估长期使用托法替布10mg每日两次对中重度银屑病患者T细胞依赖性疫苗免疫应答的影响。60例完成研究的患者接种PCV-13和破伤风类毒素疫苗后,PCV-13各血清型抗体几何平均倍数上升8.3至101.9,破伤风疫苗88%患者抗体≥2倍上升、60%≥4倍上升。结论认为多数患者可产生满意的T细胞依赖性应答。

要点

  • 长期托法替布10mg每日两次治疗下,银屑病患者对PCV-13和破伤风疫苗可产生满意应答
  • PCV-13各血清型抗体几何平均倍数上升范围8.3至101.9
  • 破伤风疫苗88%患者抗体≥2倍上升,60%≥4倍上升

核心结论

  • 多数接受托法替布治疗的中重度银屑病患者能对PCV-13和破伤风疫苗产生满意的T细胞依赖性免疫应答。

研究设计与样本

  • 研究纳入完成至少3个月连续托法替布10mg每日两次治疗的中重度银屑病患者,接种单价破伤风类毒素疫苗和13价肺炎球菌结合疫苗(PCV-13),于基线(接种前)和接种后4周评估免疫应答,共60例患者完成研究。

主要发现

  • 接种后4周,PCV-13的13个血清型抗体几何平均倍数从基线上升范围为8.3(血清型3)至101.9(血清型6A)。
  • 基线有或无淋巴细胞减少的患者中观察到相似结果。
  • 破伤风类毒素疫苗方面,51例(88%)患者抗体浓度上升≥2倍,35例(60%)患者上升≥4倍。

临床怎么用

  • 接受托法替布治疗的中重度银屑病患者可按常规接种PCV-13和破伤风类毒素疫苗,多数患者能产生满意应答。

局限性

  • 研究无安慰剂对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. METHODS: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell-dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. RESULTS: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration. LIMITATIONS: There was no placebo control. CONCLUSION: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell-dependent responses to PCV-13 and tetanus vaccines.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Korman N, Abramovits W, et al. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol. 2018. PMID: 29080806. doi:10.1016/j.jaad.2017.09.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。